![]() | Gianfranco GianfrancoShow email addressDepartment of Cardiovascular, Neural and Metabolic Sciences, Istituto Auxologico Italiano, IRCCS, 20149 Milan, Italy;, c.lombardi@auxologico.it, (C.L.);, ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Gianfranco Gianfranco:Expert Impact
Concepts for whichGianfranco Gianfrancohas direct influence:Blood pressure,Heart failure,Heart rate,Blood pressure variability,Pressure blood,Ambulatory blood,Pressure monitoring,European society.
Gianfranco Gianfranco:KOL impact
Concepts related to the work of other authors for whichfor which Gianfranco Gianfranco has influence:Blood pressure,Heart rate,Hypertensive patients,Arterial stiffness,Cardiovascular disease,Resistant hypertension,Atrial fibrillation.
KOL Resume for Gianfranco Gianfranco
Year | |
---|---|
2022 | Department of Cardiovascular, Neural and Metabolic Sciences, Istituto Auxologico Italiano, IRCCS, 20149 Milan, Italy;, (C.L.);, (G.P.);, (A.F.) Istituto Auxologico Italiano Istituto di Ricovero e Cura a Carattere scientifico (IRCCS), Ospedale San Luca, Milan, Italy (G.P.). Secretary-General, World Hypertension League, Hong Kong, China School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy ISTITUTO AUXOLOGICO ITALIANO IRCCS OSPEDALE S LUCA E UNIVERSITÀ DEGLI STUDI DI BERGAMO, MILANO; ISTITUTO AUXOLOGICO ITALIANO IRCCS OSPEDALE S LUCA, MILANO; ISTITUTO AUXOLOGICO ITALIANO IRCCS OSPEDALE S LUCA, MILANO; HOPITAL ERASME, BRUXELLES; ISTITUTO AUXOLOGICO ITALIANO IRCCS OSPEDALE S LUCA E UNIVERSITÀ DI MILANO BICOCCA, MILANO; OSPEDALE PAPA GIOVANNI XXIII, BERGAMO |
Concept | World rank |
---|---|
mission sts‐107 | #1 |
deb cli | #1 |
consultorio | #1 |
olmesartan 8 weeks | #1 |
estimate subendocardial | #1 |
56 total mortality | #1 |
osas resistant hypertension | #1 |
wearable technologies wearables | #1 |
28±6 | #1 |
distinct pathophysiology aftr | #1 |
artsana csi | #1 |
highcareandes lowlanders study | #1 |
mildahi | #1 |
hypertensionrelated morbidities | #1 |
wrist monitor hem907 | #1 |
206260 | #1 |
sdepl | #1 |
altitude winter | #1 |
mseft | #1 |
thyroid parathyroid diseases | #1 |
sbp 2 | #1 |
usual sbt | #1 |
heart failure indexes | #1 |
abpm sbp | #1 |
slowwave vasomotion | #1 |
nonsustained systolic | #1 |
wave vasomotion | #1 |
unattended automated office | #1 |
bpsmart | #1 |
article heart failure | #1 |
flight rest | #1 |
cardiovascular risk bpv | #1 |
ppg tachograms | #1 |
24 blood | #1 |
hourly blood | #1 |
teb pcwp | #1 |
smoothness tovi | #1 |
abp treatment | #1 |
rri ppg | #1 |
david‐berg study | #1 |
heart chambers geometry | #1 |
office master study | #1 |
macces cabg patients | #1 |
cutoff heart failure | #1 |
uric acid thresholds | #1 |
types bpv | #1 |
hg combination treatment | #1 |
healthy blood pressure | #1 |
patients cardioembolic risk | #1 |
apply european | #1 |
Sign-in to see all concepts, it's free! | |
Prominent publications by Gianfranco Gianfranco
OBJECTIVE: To reach a consensus on the prognostic significance of new techniques of automated blood pressure measurement.
METHODS: A Task Force on the prognostic significance of ambulatory blood pressure monitoring wrote this review in preparation for the Eighth International Consensus Conference (28-31 October 2001, Sendai, Japan). This synopsis was amended to account for opinions aired at the conference and to reflect the common ground reached in the discussions.
POINTS OF CONSENSUS: ...
Known for Blood Pressure | Task Force | Ambulatory Monitoring | Whitecoat Hypertension | Qkd Interval |
OBJECTIVE: To assess the benefits and risks of short term (<12 months) or extended (>12 months) dual antiplatelet therapy (DAPT) versus standard 12 month therapy, following percutaneous coronary intervention with drug eluting stents.
DESIGN: Meta-analysis of randomised controlled trials.
DATA SOURCES: PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature, Scopus, Web of Science, Cochrane Library, and major congress proceedings, searched from 1 January 2002 to 16 ...
Known for Drug Eluting Stents | Optimal Duration | Percutaneous Coronary | Dual Antiplatelet Therapy | Extended Dapt |
Predicting Cardiovascular Risk Using Conventional vs Ambulatory Blood Pressure in Older Patients With Systolic Hypertension
[ PUBLICATION ]
CONTEXT: The clinical use of ambulatory blood pressure (BP) monitoring requires further validation in prospective outcome studies.
OBJECTIVE: To compare the prognostic significance of conventional and ambulatory BP measurement in older patients with isolated systolic hypertension.
DESIGN: Substudy to the double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial, started in October 1988 with follow up to February 1999. The conventional BP at randomization was the ...
Known for Cardiovascular Risk | Systolic Hypertension | Ambulatory Blood | Mm Hg | Topic Reproducibility |
Blood pressure control by the nifedipine GITS–telmisartan combination in patients at high cardiovascular risk: the TALENT study
[ PUBLICATION ]
BACKGROUND: Guidelines on hypertension regard combinations between two antihypertensive drugs to be the most important treatment strategy. Because of the complementary mechanism of action and the evidence of cardiovascular protective effects they include the combination of a calcium antagonist and an angiotensin receptor antagonist among the priorital ones to employ.
AIMS: To determine in hypertensive patients at high cardiovascular risk whether combining Nifedipine GITS at low dose and ...
Known for Nifedipine Gits | Cardiovascular Risk | Telmisartan Combination | Blood Pressure | Patients Monotherapy |
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks
[ PUBLICATION ]
Aims: Blood pressure variability is associated with increased risk of cardiovascular events, particularly in high-risk patients. We assessed if variability was associated with increased risk of cardiovascular events and death in hypertensive patients at different risk levels.
Methods and results: The Valsartan Antihypertensive Long-term Use Evaluation trial was a randomized controlled trial of valsartan vs. amlodipine in patients with hypertension and different risks of cardiovascular ...
Known for Cardiovascular Events | Blood Pressure Variability | Patients Hypertension | Risk Death | 6 Months |
Relationship Between Short-Term Blood Pressure Variability and Large-Artery Stiffness in Human Hypertension
[ PUBLICATION ]
Short-term blood pressure (BP) variability predicts cardiovascular complications in hypertension, but its association with large-artery stiffness is poorly understood and confounded by methodologic issues related to the assessment of BP variations over 24 hours. Carotid-femoral pulse wave velocity (cfPWV) and 24-hour ambulatory BP were measured in 911 untreated, nondiabetic patients with uncomplicated hypertension (learning population) and in 2089 mostly treated hypertensive patients ...
Known for Term Blood | Pressure Variability | 24hour Sbp | Weighted 24 | Hypertensive Patients |
BACKGROUND AND OBJECTIVES: In 68 randomized controlled trials (RCTs), blood pressure (BP) lowering was obtained by using drugs of different classes. We have investigated whether BP lowering by any of the major drug classes is effective in reducing the cardiovascular outcomes.
METHODS: A total of 55 RCTs (19,5 267 individuals) were suitable for drug-class meta-analyses. Risk ratios and their 95% confidence intervals of seven fatal and nonfatal outcomes were estimated by a random-effects ...
Known for Outcome Incidence | Blood Pressure | Major Cardiovascular Events | Antihypertensive Agents | Heart Failure |
BACKGROUND: Antihypertensive treatment is based on randomized controlled trials (RCTs) started since 1966. Meta-analyses comprehensive of all RCTs but limited to RCTs investigating blood pressure (BP) lowering in hypertensive patients are lacking.
OBJECTIVES: Two clinical questions were investigated: the extent of different outcome reductions by BP lowering in hypertensive patients, and the proportionality of outcome reductions to SBP, DBP, and pulse pressure (PP) reductions.
METHODS: ...
Known for Outcome Incidence | Blood Pressure | Hypertensive Patients | Sbp Dbp | Lowering Rcts |
BACKGROUND: Type 2 diabetes mellitus is associated with an increased risk of hypertension, and cardiovascular and renal disease, and it has been recommended that management of hypertension should be more aggressive in presence than in absence of diabetes mellitus, but the matter is controversial at present.
OBJECTIVES: Meta-analysing all available randomized controlled trials (RCTs) to compare the effects on cardiovascular and renal outcomes of blood pressure BP lowering to different ...
Known for Diabetes Mellitus | Outcome Incidence | Cardiovascular Risk | 130 Mmhg | Lowering Treatment |
Numerous empirical studies have investigated the relationships between cardiovascular diseases (CVD) and patients' psychological well-being, with a focus almost exclusively on its dark side. Very little is known on the impact of illness severity on both negative and positive indicators of patients' well-being, as well as on the psychosocial variables that may mediate this association. Aim of the study was to investigate the impact of illness severity on depression as well as on health ...
Known for Illness Severity | Health Satisfaction | Cardiovascular Disease | Mediating Role | Efficacy Beliefs |
Difference Between Clinic and Daytime Blood Pressure Is Not a Measure of the White Coat Effect
[ PUBLICATION ]
The purpose of the present study was to evaluate whether the difference between blood pressure measured in the clinic or physician's office and the average daytime blood pressure accurately reflects the blood pressure response of the patient to the physician ("white coat effect" or "white coat hypertension"). We studied 28 hypertensive outpatients (mean age, 41.8+/-11.2 years; age range, 21 to 64 years) of 35 consecutive patients attending our hypertension clinic, in whom (1) continuous ...
Known for White Coat | Blood Pressure | Difference Clinic | Mm Hg | Physician Visit |